TIP_link_300x300.jpg
Cell and Gene Therapy Manufacturing Services Market worth $26.72 Billion, Globally, by 2030 – Comprehensive Study by The Insight Partners
September 27, 2023 10:12 ET | The Insight Partners
Pune, India, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Cell & gene therapy (CGT) programs are rapidly advancing from research & development to clinical trials and commercial approval. Establishing...
logo 600X600.png
Cell therapy Manufacturing Market to Surpass US$ 11,633.8 Million by 2030, Says Coherent Market Insights (CMI)
February 24, 2023 08:30 ET | CMI
Burlingame, Feb. 24, 2023 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global cell therapy manufacturing market is estimated to be valued at US$ 3,755.4 million in 2022 and is...
GME_18x18.jpg
Global Allogeneic Cell Therapy Market Size-Forecasts to 2027
August 22, 2022 11:31 ET | Global Market Estimates
Brooklyn, New York, Aug. 22, 2022 (GLOBE NEWSWIRE) -- According to a new market research report published by Global Market Estimates, the Global Allogeneic Cell Therapy Market is projected to grow...
Rubius_Logo.jpg
Rubius Therapeutics Announces Publication of RTX-321 Preclinical Data in Nature Communications
May 12, 2021 08:00 ET | Rubius Therapeutics
CAMBRIDGE, Mass., May 12, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...
Rubius_Logo.jpg
Rubius Therapeutics Announces Dosing of First Patient in Phase 1/2 Trial of RTX-240, an Allogeneic Cellular Therapy, for the Treatment of Solid Tumors
May 07, 2020 08:00 ET | Rubius Therapeutics
CAMBRIDGE, Mass., May 07, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...
Rubius_Logo.jpg
Rubius Therapeutics Announces Preclinical Data from Red Cell Therapeutic Oncology Programs to be Presented at the ASGCT 23rd Annual Meeting
April 29, 2020 08:00 ET | Rubius Therapeutics
CAMBRIDGE, Mass., April 29, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...
Rubius_Logo.jpg
Rubius Therapeutics Announces First Patient Dosed in Phase 1b Trial of RTX-134 for the Treatment of Patients with Phenylketonuria
January 30, 2020 08:00 ET | Rubius Therapeutics
CAMBRIDGE, Mass., Jan. 30, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...
Rubius_Logo.jpg
Rubius Therapeutics Announces 2020 Objectives and Provides Operational Update at the 38th Annual J.P. Morgan Healthcare Conference
January 13, 2020 08:00 ET | Rubius Therapeutics
RTX-240 Investigational New Drug Application for Cancer on File with U.S. Food and Drug Administration Rubius Manufacturing Facility Operational Nine Months Ahead of Schedule and Ready to Supply...
Rubius_Logo.jpg
Rubius Therapeutics Appoints Internationally Recognized Autoimmunity and Translational Immunology Leader Laurence Turka, M.D., as Chief Scientific Officer
January 08, 2020 08:00 ET | Rubius Therapeutics
CAMBRIDGE, Mass., Jan. 08, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...
Rubius_Logo.jpg
Rubius Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference
January 02, 2020 16:05 ET | Rubius Therapeutics
CAMBRIDGE, Mass., Jan. 02, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...